256 related articles for article (PubMed ID: 27748667)
1. Applicability of botulinum toxin type A in paediatric neurogenic bladder management.
Scheepe JR; Blok BF; 't Hoen LA
Curr Opin Urol; 2017 Jan; 27(1):14-19. PubMed ID: 27748667
[TBL] [Abstract][Full Text] [Related]
2. Botulinum injection is useless on fibrotic neuropathic bladders.
Tiryaki S; Yagmur I; Parlar Y; Ozel K; Akyildiz C; Avanoglu A; Ulman I
J Pediatr Urol; 2015 Feb; 11(1):27.e1-4. PubMed ID: 25448589
[TBL] [Abstract][Full Text] [Related]
3. Intradetrusor botulinum toxin injections (300 units) for the treatment of poorly compliant bladders in patients with adult neurogenic lower urinary tract dysfunction.
O'Connor RC; Johnson DP; Guralnick ML
Neurourol Urodyn; 2020 Nov; 39(8):2322-2328. PubMed ID: 32866304
[TBL] [Abstract][Full Text] [Related]
4. Botulinum Toxin Injection for Medically Refractory Neurogenic Bladder in Children: A Systematic Review.
Wu SY; Chang SJ; Yang SS; Hsu CK
Toxins (Basel); 2021 Jun; 13(7):. PubMed ID: 34203333
[TBL] [Abstract][Full Text] [Related]
5. Urodynamic Outcomes in Children after Single and Multiple Injections for Overactive and Low Compliance Neurogenic Bladder Treated with Abobotulinum Toxin A.
Naqvi S; Clothier J; Wright A; Garriboli M
J Urol; 2020 Feb; 203(2):413-419. PubMed ID: 31518199
[TBL] [Abstract][Full Text] [Related]
6. A pilot prospective study to evaluate whether the bladder morphology in cystography and/or urodynamic may help predict the response to botulinum toxin a injection in neurogenic bladder refractory to anticholinergics.
Álvares RA; Araújo ID; Sanches MD
BMC Urol; 2014 Aug; 14():66. PubMed ID: 25123234
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin for the management of bladder dysfunction.
Schurch B
Drugs; 2006; 66(10):1301-18. PubMed ID: 16903766
[TBL] [Abstract][Full Text] [Related]
8. Factors that influence the urodynamic results of botulinum toxin in the treatment of neurogenic hyperactivity.
Gutiérrez-Martín P; Vírseda-Chamorro M; Salinas Casado J; Gómez-Rodríguez A; Esteban-Fuertes M
Actas Urol Esp; 2015 May; 39(4):217-21. PubMed ID: 25582926
[TBL] [Abstract][Full Text] [Related]
9. Botulinum toxin-A (Botox) intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review.
Gamé X; Mouracade P; Chartier-Kastler E; Viehweger E; Moog R; Amarenco G; Denys P; De Seze M; Haab F; Karsenty G; Kerdraon J; Perrouin-Verbe B; Ruffion A; Soler JM; Saussine C
J Pediatr Urol; 2009 Jun; 5(3):156-64. PubMed ID: 19264554
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury.
Mehta S; Hill D; McIntyre A; Foley N; Hsieh J; Ethans K; Teasell RW; Loh E; Welk B; Wolfe D
Arch Phys Med Rehabil; 2013 Aug; 94(8):1473-81. PubMed ID: 23632286
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of electromotive drug administration in delivering botulinum toxin a in children with neuropathic detrusor overactivity-outcomes of a pilot study.
Koh C; Melling CV; Jennings C; Lewis M; Goyal A
J Pediatr Urol; 2019 Oct; 15(5):552.e1-552.e8. PubMed ID: 31326328
[TBL] [Abstract][Full Text] [Related]
12. Preoperative urodynamic factors predicting outcome of botulinum toxin-A intradetrusor injection in children with neurogenic detrusor overactivity.
Kim SW; Choi JH; Lee YS; Han SW; Im YJ
Urology; 2014 Dec; 84(6):1480-4. PubMed ID: 25432842
[TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review.
Karsenty G; Denys P; Amarenco G; De Seze M; Gamé X; Haab F; Kerdraon J; Perrouin-Verbe B; Ruffion A; Saussine C; Soler JM; Schurch B; Chartier-Kastler E
Eur Urol; 2008 Feb; 53(2):275-87. PubMed ID: 17988791
[TBL] [Abstract][Full Text] [Related]
14. Intradetrusor injections of onabotulinum toxin A (Botox®) 300 U or 200 U versus abobotulinum toxin A (Dysport®) 750 U in the management of neurogenic detrusor overactivity: A case control study.
Peyronnet B; Castel-Lacanal E; Roumiguie M; Even L; Marque P; Soulié M; Rischmann P; Game X
Neurourol Urodyn; 2017 Mar; 36(3):734-739. PubMed ID: 27037973
[TBL] [Abstract][Full Text] [Related]
15. Intravesical electromotive botulinum toxin type A administration--part II: Clinical application.
Kajbafzadeh AM; Ahmadi H; Montaser-Kouhsari L; Sharifi-Rad L; Nejat F; Bazargan-Hejazi S
Urology; 2011 Feb; 77(2):439-45. PubMed ID: 20800886
[TBL] [Abstract][Full Text] [Related]
16. Early experimental results of using a novel delivery carrier, hyaluronan-phosphatidylethanolamine (HA-PE), which may allow simple bladder instillation of botulinum toxin A as effectively as direct detrusor muscle injection.
El Shatoury MG; DeYoung L; Turley E; Yazdani A; Dave S
J Pediatr Urol; 2018 Apr; 14(2):172.e1-172.e6. PubMed ID: 29482891
[TBL] [Abstract][Full Text] [Related]
17. Management of refractory idiopathic overactive bladder: intradetrusor injection of botulinum toxin type A versus posterior tibial nerve stimulation.
Sherif H; Khalil M; Omar R
Can J Urol; 2017 Jun; 24(3):8838-8846. PubMed ID: 28646940
[TBL] [Abstract][Full Text] [Related]
18. Intravesical botulinum-A toxin in children with refractory non-neurogenic overactive bladder.
Lambregts AP; Nieuwhof-Leppink AJ; Klijn AJ; Schroeder RPJ
J Pediatr Urol; 2022 Jun; 18(3):351.e1-351.e8. PubMed ID: 35283021
[TBL] [Abstract][Full Text] [Related]
19. A Review of Botulinum Toxin A for the Treatment of Neurogenic Bladder.
Cooley LF; Kielb S
PM R; 2019 Feb; 11(2):192-200. PubMed ID: 30138720
[TBL] [Abstract][Full Text] [Related]
20. Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction.
Akbar M; Abel R; Seyler TM; Bedke J; Haferkamp A; Gerner HJ; Möhring K
BJU Int; 2007 Sep; 100(3):639-45. PubMed ID: 17532858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]